Navigation Links
InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update
Date:11/15/2011

TEL AVIV, Israel, Nov. 15, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology, today announced that it has filed its Form 10-Q for the three months ended September 30, 2011 with the U.S. Securities and Exchange Commission. The Company provided an update on progress year-to-date:

Year-to-Date Highlights

  • Year-to-date shipment volumes increased 85% compared to the first nine months of last year, reflecting increased global demand and an expanding distribution network.
  • InspireMD advanced its regulatory strategy for the U.S. approval of the MGuard stent for patients with Myocardial Infarctions by entering into a clinical trial services agreement with Harvard Clinical Research Institute, Inc., (HCRI); HCRI will manage the FDA study entitled "MGuard Stent System to Treat Patients with Acute Myocardial Infarction" on behalf of InspireMD with the goal of securing FDA approval ultimately clearing InspireMD to sell its product in the United States. The Study is expected to enroll more than 650 patients in approximately 50 clinical sites in the United States and Europe with the potential to expand the study by additional 150 patients. InspireMD expects to select a primary investigator and initiate the study in 2012.
  • On October 25, 2011, InspireMD received notice of allowance for U.S. patent 8,043,323 for "In Vivo Filter Assembly" from the U.S. Patent and Trademark Office. The patent, authored by InspireMD founders Asher Holzer, Ph.D, Ofir Paz and Eli Bar, covers the invention of in vivo filters that filter debris from a fluid stream in which the filter is disposed. MGuard is based on a stent which is wrapped with an expandable, MicroNet (mesh) made of a single knitted PET fiber.
  • The Company expanded its board of dire
    '/>"/>

  • SOURCE InspireMD
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
    2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
    3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
    4. InspireMD Boosts MGuard Production Capacity
    5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
    6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
    7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
    8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
    9. InspireMD Announces Year-to-Date 2011 Progress
    10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
    11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
    (Date:7/29/2014)... Regado Biosciences, Inc. (Nasdaq: RGDO ... clinical development of Revolixys™ Kit (previously known as REG1), ... that it will hold a conference call and live ... a.m. EDT to discuss its second quarter 2014 financial ... investors may access the conference call by dialing (877) ...
    (Date:7/29/2014)... PAUL, Minn. , July 29, 2014  EnteroMedics ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 7, ... results for the second quarter ended June 30, 2014 ... Call Details The second quarter conference call ...
    Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
    ... - New data from an,investigational study released ... Scientific Sessions showed that initial,combination therapy with ... markers of beta cell,function in patients with ... determines the ability of the body to ...
    ... RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed ... and approval of drugs for the treatment ... noted the publication of,promising results of research ... insulin-like growth factor binding protein-3,(IGFBP-3) in the ...
    Cached Medicine Technology:An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 2Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 3
    (Date:7/29/2014)... 30, 2014 VogueQueen.com, a well-known online ... the newest trends in garment fashion by providing graceful ... is selling an all-inclusive array of sexy dresses ... online, a lot of customers take price into consideration. ... That makes the purchase more affordable for all clients. ...
    (Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
    (Date:7/29/2014)... The One Minute Herpes Cure review indicates that the ... specialist. Alison Freeman wanted to show her patients some alternative ... in finding out more about this method can easily access ... is currently available in online format. , In the eBook, ... medicine tips that can help them achieve a cure for ...
    (Date:7/29/2014)... July 29, 2014 The Natural Multiple ... the inside story to Gary M. Levin’s cure program. ... cure method for this serious disorder. Levin says that ... conditions that can be found in patients. , ... surgeon. For many years, Levin has worked with patients ...
    (Date:7/29/2014)... 29, 2014 DailyGossip.org reveals in its ... is a new method of naturally overcoming sciatica, in ... the new method ensure sufferers that the cure is ... , The new method is described as very ... sciatica with an 8 minutes per day treatment plan. ...
    Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
    ... want nothing more than to get back home to ... be more emotionally taxing than the deployment. Returning ... depressive symptoms and relationship distress, and research shows the ... Leanne Knobloch (pronounced kuh-NO-block). That,s not a good thing, ...
    ... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Using ... strain of bacteria thought to be responsible for the Black ... The plague, caused by a strain of flea-borne bacteria ... centuries ago. But the variant of the bacterium behind that ...
    ... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Nearly one ... age of 18, a new study finds, and they could face ... The research doesn,t prove that so-called "child marriage" causes ... report published in the September issue of the journal Pediatrics ...
    ... not how old but how frail patients are that can predict ... young patients in poor health may have worse outcomes than older ... University of Michigan Comprehensive Cancer Center finds that patients with decreased ... to distant parts of the body. These findings may ...
    ... of measles have been reported in the United States ... in Europe, a sign the disease is making an ... is the result of unfounded fears about a link ... some parents against childhood vaccination, says Gregory Poland, M.D. ...
    ... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) ... to Iraq, Afghanistan or other war-torn countries may prime ... (PTSD), but new research suggests these changes don,t last ... anxiety disorder that develops after witnessing or surviving a ...
    Cached Medicine News:Health News:Study offers insight for returning troops and their relationships 2Health News:Study offers insight for returning troops and their relationships 3Health News:Bacterial Strain Behind 'Black Death' Plague Is Likely Extinct: Study 2Health News:Bacterial Strain Behind 'Black Death' Plague Is Likely Extinct: Study 3Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 2Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 3Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News:Mayo Clinic physician: Mistaken fear of measles shot has 'devastating' effect 2Health News:Effects of Combat Stress May Not Last as Long as Thought 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: